| Similar Articles |
|---|
 |
The Motley Fool
March 23, 2004
W.D. Crotty |
Down on Drug News? An FDA advisory on labeling antidepressants shouldn't depress drug stocks.   |
American Family Physician
January 1, 2007 |
Depression in Children and Teens How to recognize depression in your children and resources available for more information. |
The Motley Fool
June 3, 2004
Brian Gorman |
Spitzer Chases Glaxo Did the drug company GlaxoSmithKline withhold information about the effects of Paxil in children? No doubt the bad publicity will continue to hit the stock. |
The Motley Fool
September 16, 2004
Alyce Lomax |
Depressing Days for Drug Makers? Is black-box labeling of antidepressants going to curtail the mammoth industry? |
BusinessWeek
April 26, 2004
Carol Marie Cropper |
A Cloud Over Antidepressants Do some popular drugs cause suicidal behavior in teens? |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
ifeminists
May 24, 2006
Gerald K. McOscar |
ADHD Is it child abuse per se for parents to allow doctors to prescribe mind altering drugs with potentially serious or fatal psychiatric side effects to their children, no matter how challenged...or challenging? |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
American Family Physician
January 1, 2007
Shashi & Subhash Bhatia |
Childhood and Adolescent Depression Safe and effective treatment of major depression in this age group requires accurate diagnosis, suicide risk assessment, and use of evidence-based therapies. |
Nursing
May 2010
Sharon M. Valente |
Assessing patients for suicide risk This article will help you update your knowledge of suicide risk factors and prevention strategies, and provide guidelines for effective intervention. |
The Motley Fool
March 28, 2008
Brian Orelli |
Allergic Reaction to Singulair News? The FDA warns the public about potential side effects of Merck's allergy treatment Singulair. |
ifeminists
October 5, 2008
Tony Zizza |
The over-prescribing of America In writing "Stigma often hinders lifesaving discussion" for The Tennessean on Sept. 17, Dr. Dennis Morrison offers us more recycled bromides concerning suicide and the state of mental health. |
Pharmaceutical Executive
July 1, 2009
Jill Wechsler |
Safety and Security As FDA looks to balance risks and benefits, more regulations are on the horizon. |
The Motley Fool
March 19, 2009
Brian Orelli |
One Down, One to Go Sanofi-aventis slides past an FDA panel and hopes for more good news today |
Wired
September 25, 2007
Patrick Di Justo |
From Benzedrine to Abilify, Chronicling America's Love of Psychiatric Drugs A history of what Americans have used to battle depression. |
The Motley Fool
June 18, 2009
Brian Orelli |
Your Stocks Just Got Riskier It's been a busy week for the Food and Drug Administration, and not in the bust-out-the-champagne-we-got-an-approval way. Is the FDA cracking down on pharmaceutical companies? |
American Family Physician
September 15, 2002 |
Depression in Women Is depression common in women?... What are the symptoms?... What causes depression?... Symptoms of Depresssion... How is depression treated?... Are antidepressants safe for any woman with depression?... etc. |
The Motley Fool
April 26, 2011
Luke Timmerman |
FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex? |
The Motley Fool
June 11, 2009
Brian Orelli |
Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children. |
The Motley Fool
September 8, 2008
Rich Duprey |
The Coming Great Pharma Panic The FDA's drug warning list provides dangerously little information. |
Nurse Practitioner
March 2012
Vanya Hamrin et al. |
Evaluation and Management of Pediatric and Adolescent Depression The primary care setting is an appropriate venue for screening and identifying pediatric depression. Nurse practitioners can provide initial management or referral to psychiatric mental health professionals for evidence-based treatments. |
AskMen.com
January 6, 2001
Joshua Levine |
Dealing With Depression Clinical depression is an illness characterized by a cluster of feelings, thoughts and behaviors that are strikingly different from a person's normal range of feeling and functioning... |
Managed Care
November 2006 |
The Formulary Files Step therapy for antidepressants saves 11.7 percent in one year. |
Pharmaceutical Executive
April 1, 2006
Jill Wechsler |
Washington Report: A Warning Trend Washington's new answer to drug safety concerns is more warnings and more disclosure of undigested data. But warnings can go too far. Haven't FDA's critics ever heard the story of the boy who cried wolf? |
American Family Physician
November 1, 2003
Stovall & Domino |
Approaching the Suicidal Patient In an attempt to help the family physician prevent suicide, this article reviews known risk factors and offers a strategy for assessing and addressing these factors in individual patients. |
Nurse Practitioner
October 2011
Krauter & Cook |
Pharmacogenetics and the pharmacological management of depression One CYP450 enzyme, CYP2D6, is responsible for the metabolism of 30% of all drugs including many antidepressants. Phenotypes of metabolizer status affect antidepressant treatment outcomes and adverse drug reactions. |
The Motley Fool
October 19, 2010
Brian Orelli |
Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency. |
Nursing Management
March 2010
Becker & Schmidtke |
All along the watchtower: Suicide risk screening, a pilot study Patients will continue to die if healthcare organizations don't take action and appropriately assess patients at risk for suicide in general hospitals. |
BusinessWeek
November 19, 2009
Catherine Arnst |
Why Drugmakers Don't Twitter The FDA has so far failed to craft rules clarifying how pharmaceutical companies can participate in online discussions. |
American Family Physician
November 15, 2000
Son & Kirchner |
Depression in Children and Adolescents Depression among children and adolescents is common but frequently unrecognized. It affects 2 percent of prepubertal children and 5 to 8 percent of adolescents... |
The Motley Fool
August 23, 2006
S.J. Caplan |
Wyeth Feeling Happy The FDA cancels a meeting related to the market application for Wyeth's experimental antidepressant. Investors, take note. |
The Motley Fool
June 29, 2010
Brian Orelli |
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting. |
The Motley Fool
February 4, 2010
Brian Orelli |
Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct. |
Managed Care
July 2003 |
National drug bill to continue rising by 14%-18% Prescription drug spending will continue to rise between 13 and 18 percent annually over the next three years, with price inflation and higher utilization fueling the increase, Medco Health Solutions says in a new report. |
Pharmaceutical Executive
April 1, 2009
Patrick Clinton |
Dear Commissioner... Unsolicited advice for FDA's next leader: Keep it real, fight popular delusions, and somehow, please, defend the agency. |
Chemistry World
February 26, 2008
James Mitchell Crow |
Q and A: Do Antidepressants Work? A widely-reported analysis of clinical trial data for Prozac and related antidepressant drugs has claimed that the medicines work little better than chemically-inactive placebos in all but the most severely depressed patients. |
BusinessWeek
March 7, 2005
John Carey |
Side Effects Of The Drug Scares New fears give rise to a more honest look at the risks for a pill-popping nation. |
Pharmaceutical Executive
December 1, 2013 |
FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
July 12, 2011
Luke Timmerman |
Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug. |
Chemistry World
April 12, 2011
Meera Senthilingam |
How antidepressants spur brain growth Researchers have identified the mechanism by which some antidepressants stimulate the formation of new brain cells, an insight that could lead to improved drugs. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
September 9, 2010
Brian Orelli |
Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September. |
Managed Care
April 2005 |
Diabetes Costs Rise, But so Does Adherence A typical health plan can expect endocrine and diabetes agents to amount to 6% to 8% of total utilization costs, with spending on these agents to increase between 11% and 15% 2005. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
ifeminists
May 5, 2004
Tony Zizza |
Depression Screenings Don't Belong In Our Schools A recent article in the Denver Post reports Denver Health's School-Based Health Centers are screening every student - for depression - who steps inside any one of the 11 school-based "clinics." |
The Motley Fool
November 19, 2008
Brian Orelli |
Depressing News for Drugmakers Antidepressants aren't that different from each other, says a recent report. |
The Motley Fool
January 8, 2008
Brian Orelli |
A Painful Reminder From the FDA The agency issues a reminder that osteoporosis drugs can cause severe pain. |
Pharmaceutical Executive
March 1, 2006
Jill Wechsler |
Washington Report: Labels and Liability New FDA guidance aims at better communication of risks. But it creates some, too. |
The Motley Fool
January 25, 2011
Brian Orelli |
FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares. |
